

BRIAN SANDOVAL
Governor



RICHARD WHITLEY, MS
Director

MARTA JENSEN
Administrator

DEPARTMENT OF HEALTH AND HUMAN SERVICES
DIVISION OF HEALTH CARE FINANCING AND POLICY
1100 East William Street, Suite 101
Carson City, Nevada 89701
Telephone (775) 684-3676 • Fax (775) 687-3893
<http://dhcfp.nv.gov>

NOTICE OF PUBLIC MEETING – PHARMACY AND THERAPEUTICS COMMITTEE

AGENDA

Date of Publication: May 30, 2018

Date and Time of Meeting: June 28, 2018 at 1:00 PM

Name of Organization: The State of Nevada, Department of Health and Human Services (DHHS), Division of Health Care Financing and Policy (DHCFP)

Place of Meeting:

North Nevada Location:
Division of Public & Behavioral Health
4150 Technology Way, Room 303
Carson City, Nevada 89706

South Nevada Location:
Springs Preserve
333 S Valley View Blvd.
Las Vegas, Nevada 89107

Please check with staff upon arrival to verify room location

Webinar Registration: <https://optum.webex.com/optum/onstage/g.php?MTID=e560752b8f9dc86cbac9ec27d34f429cc>

OR

www.webex.com, select “Join,” enter Meeting Number 645 934 684, your name and email and then select “Join.”

A Password should not be necessary, but if asked, enter “uCdjKY\$3”

OR

Audio Only: (763) 957-6300

Event Number: 645 934 684

Follow the instructions that appear on your screen to join the teleconference. Audio will also be broadcast over the internet (VoIP).

Reasonable efforts will be made to assist and accommodate physically challenged persons desiring to attend the meeting. Please call Colleen McLachlan at: (775) 684-3722 or email cmclachlan@dncfp.nv.gov in advance but no later than two working days prior to the meeting, so that arrangements may be conveniently made.

Public comment is limited to five minutes per individual, organization or agency, but may be extended at the discretion of the Chairperson.

AGENDA

- 1. Call to Order and Roll Call**
- 2. Public Comment**
- 3. Administrative**
 - a. **For Possible Action:** Review and Approve Meeting Minutes from March 22, 2018
 - b. Status Update by the DHCFP
 1. Public Comment
- 4. Proposed New Drug Classes**
 - a. Monoclonal Antibodies for the Treatment of Respiratory Conditions
 1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by OptumRx and the DHCFP

5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL

5. Established Drug Classes

- a. Cardiovascular Agents – Antihypertensive Agents – Direct Renin Inhibitors
 1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL

6. Established Drug Classes Being Reviewed Due to the Release of New Drugs

- a. Analgesics – Opiate Agonists – Abuse Deterrent
 1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- b. Analgesics – Opiate Agonists
 1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL

- c. Hormones and Hormone Modifiers – Antidiabetic Agents – Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors and Combination
 1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL

- d. Hormones and Hormone Modifiers – Antidiabetic Agents – Insulins (Vials, Pens and Inhaled)
 1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL

- e. Hormones and Hormone Modifiers – Antidiabetic Agents – Incretin Mimetics
 1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL

- f. Respiratory Agents – Respiratory Anti-inflammatory Agents – Nasal Corticosteroids
 1. Public Comment
 2. Drug Class Review Presentation – OptumRx

3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- g. Respiratory Agents – Respiratory Anti-inflammatory – Agents Respiratory Corticosteroids
1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- h. Respiratory Agents – Respiratory Antimuscarinic Combinations.
1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- i. Gastrointestinal Agents – Antiemetics – Miscellaneous
1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP

5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
 - j. Ophthalmic Agents – Antiglaucoma Agents
 1. Public Comment
 2. Drug Class Review Presentation – OptumRx
 3. **For Possible Action:** Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
7. **Report by OptumRx on New Drugs to Market, New Generic Drugs to Market and New Line Extensions**
8. **Closing Discussion**
 - a. Public comments on any subject
 - b. Date and location of the next meeting
 - c. Adjournment

PLEASE NOTE: Items may be taken out of order at the discretion of the chairperson. Items may be combined for consideration by the public body. Items may be pulled or removed from the agenda at any time. If an action item is not completed within the time frame that has been allotted, that action item will be continued at a future time designated and announced at this meeting by the chairperson. All public comment may be limited to 5 minutes.

This notice and agenda have been posted at <http://dhcftp.nv.gov/> and notice.nv.gov/.

Notice of this public workshop meeting and draft copies of the changes will be available on or after the date of this notice at the DHCFP Web site at <http://dhcftp.nv.gov/>. The agenda posting of this meeting can be viewed at the follow locations: Carson City Central Office; Las Vegas District Office; Reno District Office; Elko District Office; Nevada State Library; Carson City Library; Churchill County Library; Las Vegas Library; Douglas County Library; Elko County Library; Esmeralda County Library; Lincoln County Library; Lyon County Library; Mineral County Library; Tonopah Public Library; Pershing County Library; Goldfield Public Library; Eureka Branch Library; Humboldt County Library; Lander County Library; Storey County Library; Washoe County Library; and White Pine County Library and may be reviewed during normal business hours.

If requested in writing, a draft copy of the changes will be mailed to you. Requests and/or written comments on the proposed changes may be sent to the Colleen McLachlan at the

May 30, 2018

Page 7

Division of Health Care Financing and Policy, 1100 E. William Street, Suite 101, Carson City, Nevada 89701.

All persons that have requested in writing to receive the Public Hearings agenda have been duly notified by mail or e-mail.